| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrea Giustina, Ioannis Karamouzis, Ilaria Patelli, Gherardo Mazziott. Octreotide for acromegaly treatment: a reappraisal. Expert opinion on pharmacotherapy. vol 14. issue 17. 2014-06-10. PMID:24124691. |
acromegaly is a rare disorder characterized by excess secretion of growth hormone (gh) generally caused by a pituitary macroadenoma and associated with reduced life expectancy if the disease is untreated. |
2014-06-10 |
2023-08-12 |
Not clear |
| Ahmet Ozkok, Esra Hatipoglu, Nevbahar Tamcelik, Burcu Balta, Ahmet Sadi Gundogdu, Mehmet Akif Ozdamar, Pinar Kadiogl. Corneal biomechanical properties of patients with acromegaly. The British journal of ophthalmology. vol 98. issue 5. 2014-06-10. PMID:24489375. |
growth hormone (gh) and insulin-like growth factor-1 (igf-1) excess in acromegaly have various effects on many organs. |
2014-06-10 |
2023-08-12 |
human |
| C Mumby, J R E Davis, J Trouillas, C E Higha. Phaeochromocytoma and Acromegaly: a unifying diagnosis. Endocrinology, diabetes & metabolism case reports. vol 2014. 2014-06-06. PMID:24897038. |
growth hormone (gh) nadir on oral glucose tolerance test (ogtt) was 2.2 ng/ml with an elevated igf1 level of 435 ng/ml (72-215), confirming acromegaly biochemically. |
2014-06-06 |
2023-08-13 |
Not clear |
| C Mumby, J R E Davis, J Trouillas, C E Higha. Phaeochromocytoma and Acromegaly: a unifying diagnosis. Endocrinology, diabetes & metabolism case reports. vol 2014. 2014-06-06. PMID:24897038. |
neuroendocrine tumours can stain positive for ghrh without coexisting acromegaly, but the resolution of patient symptoms and normalisation of serum gh and igf1 levels following surgery imply that this was functional secretion. |
2014-06-06 |
2023-08-13 |
Not clear |
| Trevor A Howlett, Debbie Willis, Gillian Walker, John A H Wass, Peter J Traine. Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clinical endocrinology. vol 79. issue 5. 2014-05-08. PMID:23574573. |
we investigated the control of gh and igf1 in acromegaly in routine clinical practice in the uk on and off medical treatment. |
2014-05-08 |
2023-08-12 |
Not clear |
| A J Varewijck, A J van der Lely, S J C M M Neggers, S W J Lamberts, L J Hofland, J A M J L Jansse. In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life. Endocrine connections. vol 3. issue 2. 2014-04-16. PMID:24692508. |
a cross-sectional study was carried out in 15 patients with active acromegaly based on clinical presentation, unsuppressed gh during an oral glucose tolerance test, and elevated total igf1 levels (>+2 s.d.). |
2014-04-16 |
2023-08-13 |
human |
| K M J A Claessen, H M Kroon, A M Pereira, N M Appelman-Dijkstra, M J Verstegen, M Kloppenburg, N A T Hamdy, N R Biermas. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. The Journal of clinical endocrinology and metabolism. vol 98. issue 12. 2014-04-14. PMID:24081732. |
in active acromegaly, pathologically elevated gh and igf-1 levels are associated with increased bone turnover and a high bone mass, the latter being sustained after normalization of gh values. |
2014-04-14 |
2023-08-12 |
Not clear |
| D K Lüdecke, P A Crock, M Bidlingmaier, F Schupper. Novel use of endogenous GH-measurement directly after transsphenoidal microsurgery in acromegaly treated with pegvisomant. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 121. issue 8. 2014-04-02. PMID:23765756. |
the gh receptor antagonist pegvisomant is increasingly used as therapy in acromegaly. |
2014-04-02 |
2023-08-12 |
Not clear |
| Deborah Lidsky, Sarah Malacarne, Maria Mavromati, Bettina Köhler Ballan, Jacques Philipp. [News in endocrinology in 2013]. Revue medicale suisse. vol 10. issue 412-413. 2014-03-31. PMID:24558895. |
transsphenoidal surgery is the treatment of choice for acromegaly due to pituitary adenoma but it is not always possible to reduce or control tumor growth, inhibit gh hypersecretion and normalize igf-i. |
2014-03-31 |
2023-08-12 |
Not clear |
| Michèle d'Herbomez, Catherine Bauters, Christine Cortet-Rudelli, Didier Dewailly, Christine Docao, Jean-Louis Wémea. [Biomarkers in endocrinology]. Presse medicale (Paris, France : 1983). vol 43. issue 1. 2014-03-25. PMID:24342177. |
serum igf1 is a reliable measure of integrated gh concentrations in patients with acromegaly. |
2014-03-25 |
2023-08-12 |
Not clear |
| Subramanian Kannan, Laurence Kenned. Diagnosis of acromegaly: state of the art. Expert opinion on medical diagnostics. vol 7. issue 5. 2014-03-17. PMID:23971897. |
biochemical diagnosis of acromegaly relies on measurement of insulin-like growth factor-1 (igf-1) and growth hormone (gh). |
2014-03-17 |
2023-08-12 |
Not clear |
| Subramanian Kannan, Laurence Kenned. Diagnosis of acromegaly: state of the art. Expert opinion on medical diagnostics. vol 7. issue 5. 2014-03-17. PMID:23971897. |
an elevated igf-1 level above the age- and gender-specific normal range and nonsuppression of gh to oral glucose load to a nadir < 0.4 ng/ml in sensitive assays are currently considered diagnostic of acromegaly. |
2014-03-17 |
2023-08-12 |
Not clear |
| Dominic Cavlan, Shanti Vijayaraghavan, Susan Gelding, William Drak. GH replacement causing acute hyperglycaemia and ketonuria in a type 1 diabetic patient. Endocrinology, diabetes & metabolism case reports. vol 2013. 2014-03-11. PMID:24616775. |
a state of insulin resistance is common to the clinical conditions of both chronic growth hormone (gh) deficiency and gh excess (acromegaly). |
2014-03-11 |
2023-08-12 |
Not clear |
| Derya Burcu Hazer, Serhat Işık, Dilek Berker, Serdar Güler, Alper Gürlek, Taşkın Yücel, Mustafa Berke. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria. Journal of neurosurgery. vol 119. issue 6. 2014-02-24. PMID:24074496. |
acromegaly is a disease that has significant morbidity and mortality related to high levels of growth hormone (gh) and insulin-like growth factor-i (igf-i), and is usually caused by pituitary adenomas. |
2014-02-24 |
2023-08-12 |
Not clear |
| F Tarhan, G Koç, N K Erdoğan, G Orü. Hand measurements in the follow-up of acromegaly. JBR-BTR : organe de la Societe royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR). vol 96. issue 5. 2014-02-20. PMID:24479296. |
acromegaly is a chronic progressive disease that originates from the increased secretion of the insulin-like growth-hormone (igf-1) secondary to the hypersecretion of the growth hormone (gh). |
2014-02-20 |
2023-08-12 |
Not clear |
| Ling Wu, Sa V Ho, Wei Wang, Jianping Gao, Guifeng Zhang, Zhiguo Su, Tao H. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior. International journal of pharmaceutics. vol 453. issue 2. 2014-02-11. PMID:23796830. |
growth hormone antagonist (gha), an analog of growth hormone (gh), can inhibit gh action and treat acromegaly. |
2014-02-11 |
2023-08-12 |
Not clear |
| Tove Lekva, Jens Petter Berg, Ansgar Heck, Stine Lyngvi Fougner, Ole Kristoffer Olstad, Geir Ringstad, Jens Bollerslev, Thor Uelan. Attenuated RORC expression in the presence of EMT progression in somatotroph adenomas following treatment with somatostatin analogs is associated with poor clinical recovery. PloS one. vol 8. issue 6. 2014-02-07. PMID:23825587. |
somatostatin analogs (sa) have been established as the first line medical treatment for acromegaly, but following long-term treatment, sa normalizes gh and igf-i levels in only 40-60% of patients. |
2014-02-07 |
2023-08-12 |
Not clear |
| Hai Sun, Jessica Brzana, Chris G Yedinak, Sakir H Gultekin, Johnny B Delashaw, Maria Fleseri. Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly. Journal of neurological surgery. Part B, Skull base. vol 75. issue 1. 2014-02-05. PMID:24498589. |
objectives to analyze surgical outcomes and predictive factors of disease remission in acromegaly patients who underwent microscopic transsphenoidal surgery (tss) for a growth hormone (gh)-secreting adenoma. |
2014-02-05 |
2023-08-12 |
Not clear |
| Ludovica F S Grasso, Rosario Pivonello, Annamaria Cola. Investigational therapies for acromegaly. Expert opinion on investigational drugs. vol 22. issue 8. 2014-02-04. PMID:23731031. |
the treatment of acromegaly aims at normalizing growth hormone (gh) and insulin-like growth factor (igf-i) levels and controlling tumor growth. |
2014-02-04 |
2023-08-12 |
Not clear |
| Marianne Anderse. Management of endocrine disease: GH excess: diagnosis and medical therapy. European journal of endocrinology. vol 170. issue 1. 2014-01-27. PMID:24144967. |
acromegaly is predominantly caused by a pituitary adenoma, which secretes an excess of gh resulting in increased igf1 levels. |
2014-01-27 |
2023-08-12 |
human |